Canaccord Genuity downgraded Quanterix’s stock from Buy to Hold, cutting its price target from $12 to $5 after the company's Q2 2025 revenues fell 29% year-over-year due to weak pharmaceutical and academic end markets. The integration of its recent acquisition of Akoya Biosciences faces uncertainty following executive departures, threatening expected synergies and casting doubt on Quanterix’s 2026 breakeven goals. Revenue guidance was lowered, contributing to cautious near-term outlooks despite optimism about long-term potential in diagnostics.